International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 073-078
Does Fascin Expression in Diffuse Large B-Cell Lymphomas have a Clinical Impact in Patients Treated with Anthracyclin-Based Chemotherapy Plus Rituximab?

Nazım E. KOCER1, Fatih KOSE2, Fazilet KAYASELCUK1, Ayberk BESEN3, Huseyin MERTSOYLU3, Ozgur OZYILKAN3, Ilhan TUNCER1

1Baskent University Adana Research and Medical Center, Department of Pathology, Adana, TURKEY
2Sanliurfa Research and Education Hospital, Department of Oncology, Sanliurfa, TURKEY
3Baskent University Adana Research and Medical Center, Department of Medical Oncology, Adana, TURKEY

Keywords: Fascin, Non-Hodgkin lymphoma, Prognosis
Fascin is an actin-bundling protein that is expressed by dendritic cells of the lymphoid tissue. Fascin expression is also seen in the neoplastic cells of classical Hodgkin lymphomas, nearly half of the anaplastic lymphomas and in some diffuse large B-cell lymphomas. We aimed to investigate the clinical significance of fascin expression in CD20 positive diffuse large B-cell lymphomas (DLBCL) in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab (R-CHOP). Thirtyfour of the 55 patients included in the study showed fascin expression, 16 of them being diffuse and strong. There was no statistically significant correlation between fascin expression and overall survival and disease-free survival, sex, disease stage, chemotherapy response, whether or not having bulky disease, extranodal involvement, and international prognostic index (IPI) score. The study has failed to show prognostic significance of fascin expression in DLBCL patients treated with R-CHOP. However, because of the alterations in fascin expression in a variety of benign and malignant lymphoid entities, regardless of its prognostic impact, studies on fascin expression may help us to understand tumor biology of lymphomas better.